ArticleBMC ophthalmology2025
Efficacy and safety of PEI combined with goniosynechialysis and goniotomy in the treatment of acute primary angle closure glaucoma.
Article in BMC ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
objectiveTo evaluate the efficacy and safety profile of combined phacoemulsification with intraocular lens implantation (PEI), goniosynechialysis (GSL), and goniotomy (GT) in managing acute primary angle-closure glaucoma (APACG) with cataract.
methodsThis prospective case series enrolled 53 eyes from 53 APACG patients (mean age 66.43 ± 8.74 years) at Fuzhou Eye Hospital (2022-2024). All subjects underwent triple surgery (PEI + GSL + GT). Primary endpoints included intraocular pressure (IOP) reduction, anti-glaucoma medication(AGM) burden, and complications over 36 months. Surgical success was defined as IOP 5-21 mmHg with ≥ 20% reduction from the baseline without vision-threatening complications. Statistical analyses employed paired t-tests and Wilcoxon signed-rank tests.
resultsAt 36 months postoperatively, the qualified success rate(IOP control with medications) reached 76.92%. Mean IOP decreased from 38.52 ± 10.56 mmHg preoperatively to 17.12 ± 4.54 mmHg at 36 months (Δ55.6%, P < 0.001), paralleled by a 71.8% reduction in AGM(from 3.02 ± 0.6 to 0.85 ± 0.8 agents, P < 0.001). Postoperative complications included transient IOP elevation (26.42%, 14/53), corneal edema (15.09%, 8/53), and anterior chamber hemorrhage (11.32%, 6/53), all managed conservatively without sight-threatening events or secondary surgical interventions.
conclusionsIn this study, PEI + GSL + GT demonstrates significant reductions in IOP and medication burden in APACG. This minimally invasive approach integrates triple therapeutic mechanisms, namely cataract extraction, peripheral anterior synechiolysis (PAS) and trabecular meshwork excision, to reconstruct physiological outflow pathways. This represents a safe surgical alternative. It is recommended that further large-scale multicentre randomised trials are conducted in order to validate the efficacy of the treatment in the APACG and to standardise optimised surgical protocols.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.